Beijing Airdoc Technology Co Ltd (2251) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.1B
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 3 days ago
Share price −8.5% over the past month.
A solid business, but screening 25% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$8.59). The favourable scenario is already priced in.
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (HK$4.54 to HK$8.59) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
57‑month range HK$8.35 – HK$68.00 · fair‑value band HK$4.54 – HK$8.59 · the HK$9.15 price screens above the HK$6.87 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Beijing Airdoc Technology Co Ltd (2251) currently trades at HK$9.15, while our model-based Fair Value estimate is HK$6.87, implying the stock looks roughly 24.9% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Beijing Airdoc Technology Co Ltd generated revenue of HK$173M at a net margin of -14.4%. Revenue grew 42.9% year over year. It earns a return on equity of -2.0%. The balance sheet holds a net cash position of HK$554M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$4.54 (bear case) to HK$8.59 (bull case); at HK$9.15, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -25%, 2251 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 2251 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 24
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally.
Full company description
Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. It offers AI-FUNDUSCAMERA-P, a portable, automated, and self-service fundus camera that enables retinal image acquisition; AI-FUNDUSCAMERA-U, a portable fundus camera for the popularization of eye health services; and AI-FUNDUSCAMERA-H, a multimodal health scanner integrating biosensors. The company also provides AI-FUNDUSCAMERA-M, a portable intelligent image capture terminal; Airdoc-AIFUNDUS products for auxiliary diagnostic services to tertiary hospitals, primary healthcare institutions, and health checkup centers; and Airdoc vision rehabilitation instrument, a medical device to prevent axial myopia and aids in the auxiliary treatment of myopia. In addition, it offers Airdoc Neuro-AI, a non-contact measurement product for stress resilience, and physiological and psychological stress; risk assessments of retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beijing Airdoc Technology Co Ltd reported revenue of HK$173M in FY2025 versus HK$115M in FY2021, a compound +10.7%/yr. Reported net income was −HK$25.0M in FY2025.
2251 screens 25% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 125 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $58.48 | $17.18 | -71% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare Beijing Airdoc Technology Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beijing Airdoc Technology Co Ltd (2251) overvalued or undervalued?
What is the fair value of 2251?
What is the quality score of 2251?
What is the revenue of Beijing Airdoc Technology Co Ltd (2251)?
What is the net profit margin of 2251?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beijing Airdoc Technology Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.